CollPlant Biotechnologies Files 6-K Report

Ticker: CLGN · Form: 6-K · Filed: Sep 30, 2025 · CIK: 1631487

Sentiment: neutral

Topics: sec-filing, foreign-private-issuer, reporting

TL;DR

CollPlant filed a 6-K on 9/30/25, standard foreign issuer report.

AI Summary

CollPlant Biotechnologies Ltd. filed a Form 6-K on September 30, 2025, reporting for the month of September 2025. The filing is a report of a foreign private issuer and incorporates by reference the first and fourth paragraphs of an attached press release into its Registration Statements. The company's principal executive office is located at 4 Oppenheimer St, Weizmann Science Park, Rehovot, Israel.

Why It Matters

This filing indicates ongoing reporting requirements for CollPlant Biotechnologies Ltd. as a foreign private issuer, providing updates to the SEC.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer and does not contain significant new financial or operational information.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers that is required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.

What is the filing date of this Form 6-K?

This Form 6-K was filed on September 30, 2025.

What is the reporting period for this Form 6-K?

The reporting period for this Form 6-K is the month of September 2025.

Where is CollPlant Biotechnologies Ltd.'s principal executive office located?

CollPlant Biotechnologies Ltd.'s principal executive office is located at 4 Oppenheimer St, Weizmann Science Park, Rehovot, Israel.

What is the SEC file number for CollPlant Biotechnologies Ltd.?

The SEC file number for CollPlant Biotechnologies Ltd. is 001-38370.

Filing Stats: 270 words · 1 min read · ~1 pages · Grade level 14.2 · Accepted 2025-09-30 07:22:58

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. COLLPLANT BIOTECHNOLOGIES LTD. Date: September 30, 2025 By: /s/ Eran Rotem Name: Eran Rotem Title: Deputy CEO and Chief Financial Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing